Clinical Trial

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-14.
Status change: Not Yet Recruiting → Recruiting 2025-06-12
Trial Details
NCT Number NCT06937996
Lead Sponsor Englewood Hospital and Medical Center
Conditions Pancreatic Cancer Non-resectable
Enrollment 25 participants
Start Date 2025-05-13
Primary Completion 2035-05-31 (estimated)
Study Completion 2035-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-17